SCHEMBL5536444

SCHEMBL5536444

CCCC(=O)Nc1ccccc1[O]

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.69
HTT P42858 1/20 0.59
CETP P11597 2/20 0.57
GAA P10253 1/20 0.56
ALDH1A1 P00352 3/20 0.54
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
LMNA P02545 2/20 0.53
MEN1 O00255 1/20 0.53
THRA P10827 1/20 0.53
THRB P10828 1/20 0.53
KMT2A Q03164 1/20 0.53
TSHR P16473 1/20 0.50
TP53 P04637 1/20 0.50
PARP14 Q460N5 1/20 0.50
MTNR1B P49286 1/20 0.50
CYP2C19 P33261 1/20 0.50
SOAT1 P35610 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78300 0.86 CETP (0.73) CETPLMNAMEN1KMT2ATSHR
SCHEMBL10703263 0.86 CETP (0.73) CETPLMNAMEN1KMT2ATSHR
SCHEMBL5542638 0.85 ALDH1A1 (0.53) MAPK1CETPGAAALDH1A1MAPT
SCHEMBL29315244 0.81 MAPK1 (1.00) MAPK1HTTCETPGAAALDH1A1
SCHEMBL7750852 0.81 HDAC3 (0.71) MAPK1HTTGAAALDH1A1MAPT
SCHEMBL29721986 0.81 MAPK1 (0.69) MAPK1HTTCETPGAAALDH1A1
SCHEMBL5536448 0.81 MAPK1 (0.69) MAPK1HTTCETPGAAALDH1A1
SCHEMBL6658490 0.81 MAPK1 (0.69) MAPK1HTTGAAALDH1A1MAPT
SCHEMBL9850229 0.81 CYP2C19 (0.62) MAPK1GAAMAPTMEN1KMT2A
SCHEMBL12284937 0.81 ALDH1A1 (0.69) MAPK1HTTCETPGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
US-6989439-B2 Color developing agent, azo dye, silver halide photographic light-sensitive material, and image-forming method FUJI PHOTO FILM CO., LTD. (JP) 2006-01-24 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-20030204094-A1 Color developing agent, azo dye, silver halide photographic light-sensitive material, and image-forming method FUJI PHOTO FILM CO., LTD. 2003-10-30 US disclosed
US-6555691-B2 Absorption characteristics, and which is high in fastness to light, heat, humidity, air, chemicals FUJI PHOTO FILM CO., LTD. (JP) 2003-04-29 US disclosed
US-20020146651-A1 Color developing agent, azo dye, silver halide photographic light-sensitive material, and image-forming method FUJIFILM CORPORATION (JP) 2002-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030204094-A1 Color developing agent, azo dye, silver halide photographic light-sensitive material, and image-forming method IK, AIPL1, CRY1 MAPK1 913/4885HTT 1411/4885CETP 2451/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPK1 1392/4885HTT 4644/4885CETP 4769/4885
US-20020146651-A1 Color developing agent, azo dye, silver halide photographic light-sensitive material, and image-forming method IK, AIPL1, CRY1 MAPK1 913/4885HTT 1411/4885CETP 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.